Trellis Bioscience Inc

Trellis Bioscience is a clinical-stage company focused on discovering and developing native human monoclonal antibodies to treat and prevent drug-resistant, life-threatening infectious diseases. Antibodies are the immune systems most potent natural weapon against disease. Trelliss innovative proprietary technology CellSpotTM overcomes technical obstacles that have long hindered exploiting the full human antibody repertoire. This ideal source of drugs focuses on the selection of elite antibodies that bind highly conserved target epitopes with high affinity. TRL1068 is a native human monoclonal antibody (for intravenous delivery) whose target is a family of bacterial proteins (DNABII) that play a critical role in maintaining the structural integrity of biofilms by anchoring extracellular bacterial DNA (eDNA) from dead bacteria within the biofilm matrix. TRL1068 binds at high affinity (Kd ~50 pM) to a highly conserved epitope found in nearly all medically significant bacteria, includ...